ArticleJournal of inflammation research2026
Association of Naples Prognostic Score with Survival in Patients with Inoperable Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy Combined with Immunotherapy.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to determine whether the Naples Prognostic Score (NPS) is an independent predictor of overall survival (OS) and progression-free survival (PFS) in patients with unresectable esophageal squamous cell carcinoma (ESCC) undergoing chemoradiotherapy combined with immunotherapy. Materials and Methods: We analyzed 139 patients with inoperable ESCC undergoing chemoradiotherapy combined with immunotherapy between January 2020 and November 2024. We systematically evaluated the associations between NPS categories and clinical features across these cohorts. Kaplan-Meier analysis was employed to generate survival curves stratified by NPS. Univariate and multivariate Cox models assessed NPS as an independent predictor of OS and PFS for risk stratification. Results: Stratification analysis based on the NPS revealed distinct survival outcomes: the median OS was 23 months for Group 0, 17.5 months for Group 1, and 11 months for Group 2. The corresponding PFS durations were 19.5 months (Group 0), 15 months (Group 1), and 9 months (Group 2), respectively. The prognostic value of NPS was confirmed by receiver operating characteristic (ROC) curve analysis, which yielded an area under the curve (AUC) of 0.701 (P < 0.05). Importantly, multivariate Cox regression analysis established NPS as an independent prognostic factor for both OS (HR: 2.404; 95% CI: 1.411-4.095; P < 0.01) and PFS (HR: 2.203; 95% CI: 1.321-3.674; P = 0.02). These results highlight the clinical significance of NPS in prognostic assessment and treatment strategy formulation for patients with inoperable ESCC. Conclusion: The NPS has been demonstrated to be a reliable prognostic tool in unresectable ESCC. It provides a practical framework for baseline risk stratification at diagnosis to identify high-risk patients who may benefit from intensified nutritional support, closer surveillance, or enrollment in novel immunotherapy trials, thereby guiding personalized treatment and optimizing resource use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.